Brokerages Set Kenvue Inc. (NYSE:KVUE) Price Target at $19.33

Kenvue Inc. (NYSE:KVUE) has received an average recommendation of “Hold” from the sixteen ratings firms that are currently covering the company, Marketbeat reports. Twelve investment analysts have rated the stock with a hold recommendation, three have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $19.3333.

KVUE has been the subject of several recent research reports. Zacks Research upgraded shares of Kenvue from a “hold” rating to a “strong-buy” rating in a report on Friday, May 8th. Argus raised Kenvue to a “hold” rating in a report on Friday, March 6th. UBS Group dropped their price objective on shares of Kenvue from $19.00 to $18.00 and set a “neutral” rating on the stock in a report on Tuesday, April 7th. Barclays reduced their target price on Kenvue from $19.00 to $18.00 and set an “equal weight” rating for the company in a research note on Tuesday, April 14th. Finally, Weiss Ratings upgraded Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, June 15th.

Kenvue Stock Performance

KVUE stock opened at $19.81 on Friday. Kenvue has a twelve month low of $14.02 and a twelve month high of $22.87. The business’s fifty day simple moving average is $17.81 and its two-hundred day simple moving average is $17.70. The firm has a market cap of $38.03 billion, a price-to-earnings ratio of 23.30, a PEG ratio of 1.47 and a beta of 0.47. The company has a quick ratio of 0.70, a current ratio of 0.98 and a debt-to-equity ratio of 0.67.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Thursday, May 7th. The company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.05. The company had revenue of $3.91 billion during the quarter, compared to analysts’ expectations of $3.84 billion. Kenvue had a net margin of 10.61% and a return on equity of 20.81%. The firm’s quarterly revenue was up 4.5% on a year-over-year basis. During the same period in the previous year, the company earned $0.24 EPS. Analysts predict that Kenvue will post 1.16 earnings per share for the current year.

Kenvue Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, May 27th. Stockholders of record on Wednesday, May 13th were issued a $0.2075 dividend. This represents a $0.83 annualized dividend and a dividend yield of 4.2%. The ex-dividend date of this dividend was Wednesday, May 13th. Kenvue’s payout ratio is 97.65%.

Insider Transactions at Kenvue

In other Kenvue news, General Counsel Matthew Orlando sold 38,491 shares of the company’s stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $17.66, for a total value of $679,751.06. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 1.59% of the company’s stock.

Institutional Investors Weigh In On Kenvue

Several hedge funds have recently modified their holdings of KVUE. Oak Thistle LLC acquired a new position in shares of Kenvue during the 4th quarter worth approximately $1,563,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Kenvue by 25.8% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 410,874 shares of the company’s stock worth $7,088,000 after buying an additional 84,219 shares in the last quarter. SG Americas Securities LLC boosted its holdings in shares of Kenvue by 3,889.9% during the 4th quarter. SG Americas Securities LLC now owns 3,075,723 shares of the company’s stock worth $53,056,000 after purchasing an additional 2,998,635 shares during the last quarter. Moors & Cabot Inc. boosted its stake in Kenvue by 66.9% during the third quarter. Moors & Cabot Inc. now owns 313,122 shares of the company’s stock worth $5,082,000 after buying an additional 125,517 shares during the last quarter. Finally, Cohen Capital Management Inc. acquired a new position in shares of Kenvue during the 4th quarter valued at about $2,448,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.